Drugs / SIM0610
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07348211 | Jan 2026 → Dec 2027 expected | colorectal cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, non-small cell lung carcinoma | Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-23 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory SIM0610, Simcere Zaiming's a Bispecific Antibody-Drug Conjugate Approved for Clinical Trials simcere.com ↗
SIM0610 has received an approval from the National Medical Products Administration (NMPA) to enter clinical trials. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-01-20 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Simcere Zaiming's a Bispecific ADC SIM0610 Doses First Patient in a Phase I Clinical Trial simcere.com ↗ |
| 2025-12-23 | Jiangsu Simcere Pharmaceutical Co., Ltd. | SIM0610, Simcere Zaiming's a Bispecific Antibody-Drug Conjugate Approved for Clinical Trials simcere.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIM0610 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07348211 ↗ |
| Route | Intravenous | “intravenous infusion” NCT07348211 ↗ |